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Abstract
Background: World Health Organization (WHO) recommends tuberculosis (TB) screening at HIV diagnosis. We evaluated
the inclusion of rapid urine lipoarabinomannan (LAM) testing in TB screening algorithms.
Methods: We enrolled ART-naïve adults who screened HIV-infected in KwaZulu-Natal, assessed TB-related
symptoms (cough, fever, night sweats, weight loss), and obtained sputum specimens for mycobacterial culture.
Trained nurses performed clinic-based urine LAM testing using a rapid assay. We used diagnostic accuracy,
negative predictive value (NPV), and negative likelihood ratio, stratified by CD4 count, to evaluate screening for
culture-positive TB.
Results: Among 675 HIV-infected adults with median CD4 of 213/mm3 (interquartile range 85-360/mm3), 123
(18%) had culture-confirmed pulmonary TB. The WHO-recommended algorithm of any TB-related symptom had
a sensitivity of 77% [95% confidence interval (CI) 69-84%] and NPV of 89% (95% CI 84-92%) for identifying active
pulmonary TB. Including the LAM assay improved sensitivity (83%; 95% CI 75-89%) and NPV (91%; 95% CI 86-94%),
while decreasing the negative likelihood ratio (0.45 versus 0.57). Among participants with CD4 < 100/mm3, including
urine LAM testing improved the negative predictive value of symptom based screening from 83% to 87%. All
screening algorithms with urine LAM performed better among participants with CD4 < 100/mm3, compared to
those with CD4 ≥ 100/mm3.
Conclusion: Clinic-based urine LAM screening increased the sensitivity of symptom-based screening by 6%
among ART-naïve HIV-infected adults in a TB-endemic setting, thereby providing marginal benefit.
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Background
Over 9 million people develop active Mycobacterium
tuberculosis (TB) infection each year, and TB remains a
leading cause of HIV-related mortality [1, 2]. In 2006,
the World Health Organization (WHO) suggested sys-
tematic screening for active TB in HIV-infected adults
by assessing the presence of a cough for at least two
weeks [3]. In 2011, following a meta-analysis of 12 ob-
servational studies, WHO recommended systematic
screening by assessing the presence of any TB-related
symptom—current cough, fever, night sweats, and
weight loss [4–7]. Symptom-based screening misses ap-
proximately one-quarter of active TB cases among
HIV-infected adults [7], and a more recent study sug-
gested this might be as high as 76% of active TB cases
in western South Africa [8]. The Xpert® MTB/RIF assay
has been endorsed by the WHO as the primary diag-
nostic test for HIV-associated pulmonary TB among
those with symptoms, but is not recommended for use
as a screening test. [9] A better screening strategy for
HIV-associated TB is needed to accurately initiate anti-
TB treatment for active disease or isoniazid preventive
therapy for latent infections [10].
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A rapid urine lateral flow assay to detect lipoarabino-
mannan (LAM), a glycolipid released from the cell wall
of TB, has been shown to reduce mortality among HIV-
infected hospitalized patients with TB-related symptoms
when used to guide anti-TB treatment [11, 12]. In two
clinic-based studies, we demonstrated that the rapid
urine LAM assay had poor overall diagnostic sensitivity
(28-41%) to be used as a stand-alone TB screening test
at HIV diagnosis [13, 14]. With similar results from an-
other outpatient screening study [15, 16], the WHO re-
cently recommended against using the urine LAM assay
as a TB screening test. [17] However, since the rapid
LAM assay can be easily performed by nurses in a clinic
[13, 14], we sought to determine if urine LAM testing
might augment symptom-based TB screening at HIV
diagnosis in a high TB-endemic region of South Africa.
Methods
Study design and participant selection
We conducted a prospective, clinic-based study enrolling
consecutive ART-naïve HIV-infected adults in the ambu-
latory clinical areas of two hospitals and two municipal
health centers in KwaZulu-Natal, South Africa from
October 2011 to January 2014. The parent study has
been described in detail [18]. Eligible participants were
adults (≥18 years), not known to be pregnant, and not
having received anti-TB therapy within three months.
Ethics committees of the two local hospitals (McCord
Hospital and St. Mary’s Hospital) and Partners Health-
Care in Boston [Protocol #: 2006-P-001379/40] approved
the study, and all participants provided written informed
consent.
Study procedures
Prior to study commencement, a representative from
Alere Inc., the manufacturer of the rapid LAM assay,
conducted a training session for study nurses. The ses-
sion reviewed the procedures and interpretation of the
Determine™ TB LAM assay (Alere Inc., Waltham, USA),
and study nurses practiced performing and interpreting
the urine LAM assay until comfortable. Throughout the
study, LAM tests and reagents were maintained in a
sealed pouch and stored out of direct sunlight, in ac-
cordance with the manufacturer’s specifications. Regular
oversight of the nurses’ LAM testing procedures ensured
continued testing competence and proficiency.
At participant enrollment, trained study nurses col-
lected demographic and clinical information, including
TB-related symptoms—current cough, fever, night
sweats, and weight loss. Study nurses tested urine sam-
ples for LAM using the Determine™ TB LAM assay and
interpreted results after 25 minutes. Participants pro-
vided one respiratory sputum sample, and those unable
to provide an expectorated sputum sample received
sputum induction with 3% hypertonic saline using a
nebulizer (WH-802, Yuehua Medical Instrument Factory
Co.; Guangdong, China). Sputum samples were deconta-
minated with N-acetyl L Cysteine and NaOH to a final
concentration of 1.25% before being centrifuged at 3,000
revs for 20 minutes and resuspended in 1 ml of 7H9
broth. 0.5 ml of the suspension was inoculated into Bac-
tec™ 960 mycobacterial growth indicator tubes (MGIT™)
(BD; Franklin Lakes, USA), and solid culture Middleb-
rook 7H11 agar medium. M. tuberculosis was confirmed
using niacin and nitrate testing. Participants received
chest radiography, as indicated, which was interpreted
by a certified radiologist. All participants were offered
treatment in accordance with local and South African
Department of Health guidelines [19].
Statistical analyses
Participants were considered culture-positive if M. tuber-
culosis was identified from either liquid or solid culture
media, and we used culture of sputum as the accepted
gold-standard diagnostic test. [20] We categorized
LAM test results as positive vs. negative, using the
manufacturer’s 5-grade reference card. We defined a
positive LAM test as grade 1 or higher, since this study
was conducted before the reference card was changed
to grade 2 or higher and in order to maximize diagnos-
tic sensitivity for screening algorithms. We calculated
diagnostic sensitivity, specificity, and negative predict-
ive values of various screening algorithms, both with
and without the urine LAM assay. Combined algo-
rithms allowed for either screening test modality to be
positive, since requiring multiple modalities to be posi-
tive lowered diagnostic sensitivity to an unacceptable
level (29%) for a screening algorithm. We stratified al-
gorithms above and below CD4 100/mm3. We used
Fisher’s exact test to compare diagnostic sensitivity,
specificity, and negative predictive value between
groups. We also calculated negative likelihood ratios
[the probability of a person who has the disease testing
negative divided by the probability of a person who
does not have the disease testing negative; (1-sensitiv-
ity/specificity)] to determine whether a test result chan-
ged the probability of excluding disease. The formula
for calculating negative likelihood ratio includes both
sensitivity and specificity, so a reduced value (< 1) indi-
cates a favorable balance between sensitivity and speci-
ficity for a diagnostic screening “rule out” test. The
WHO considers the negative predictive value (NPV;
the proportion of algorithm-negative subjects who
proved NOT to have TB) to be the most important pa-
rameters for a screening algorithm to exclude active TB
disease [6]. We used the likelihood ratio to generate
post-test probabilities based on estimated population
TB prevalences of 5%, 10% and 20%. We calculated
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exact 95% confidence intervals (CI), reported two-
tailed p-values (α = 0.05), and used SAS 9.4 (Cary,
USA).
Results
We enrolled 757 ART-naïve HIV-infected adults. After
excluding 31 people without a urine specimen, and 51
people who had no mycobacterial culture results, our
analyses included 675 adults. Mean age was 34 years
(standard deviation ±10 years), 359 (53%) participants
were male, 58 (9%) participants reported a prior TB in-
fection, 165 (24%) participants were current smokers,
and 3 (< 1%) participants were taking a diuretic medica-
tion (Table 1). The median CD4 count was 213/mm3
(interquartile range 85-360/mm3).
Overall, 425 (63%) participants reported ≥ 1 TB-related
symptom, and each TB-related symptom was reported by
31-39% of participants. Fifty-two (8%) participants had an
abnormal chest x-ray, 36 (5%) people were sputum smear
AFB positive, and 89 (13%) participants were positive by a
single urine LAM assay. 123 people had culture confirmed
pulmonary TB, and the estimated prevalence of culture-
confirmed pulmonary TB was 18.2% (95% CI 15-21%).
Prevalence of TB was 30% (71/238) and 12% (52/437)
among those with CD4 < 100/mm3 and CD4 ≥ 100/
mm3, respectively.
The diagnostic sensitivity of presence of a cough
alone was 54% (95% CI 44-63%) (Table 2). The WHO-
recommended symptom-based screening algorithm (i.e.
presence of any TB-related symptom) had a diagnostic
sensitivity of 77% (95% CI 69-84%) and specificity of
40% (95% CI 36-44%). The combination of any TB-
related symptom or abnormal chest radiography had
83% (95% CI 75-89%) sensitivity. The negative predict-
ive value was 89% (95% CI 84-92%) for symptom-based
screening, and 91% (95% CI 87-95%) when including
chest radiography.
The urine LAM assay identified 25% (7/28) of TB-
infected adults who did not have any TB-related symp-
tom. The diagnostic sensitivity when incorporating the
urine LAM assay with symptom-based screening was
83% (95% CI 75-89%), and with symptom-based screen-
ing plus chest radiography was 87% (95% CI 80-92%).
Diagnostic specificity decreased by 2-3% in both algo-
rithms, and was 95% among participants without TB-
related symptoms. The addition of the urine LAM assay
increased the negative predictive value by 2% in both
screening algorithms. The highest negative predictive
values were any TB-related symptom or urine LAM
positive (91%; 95% CI 86-94%), and a combination of
symptom screening, urine LAM, and chest radiography
(93%; 95% CI 89-96%).
All screening algorithms, except those with current
cough as the only TB-symptom, had higher diagnostic
sensitivity among participants with CD4 < 100/mm3,
as compared to those with CD4 ≥ 100/mm3 (Table 3).
These differences were significant for symptom-based
screening (p = 0.05) and symptoms plus chest radiog-
raphy (p = 0.03). All algorithms had significantly lower
diagnostic specificities among participants with CD4
< 100/mm3 (p-values <0.001). A combination of symp-
tom screening, urine LAM, and chest radiography had
a negative predictive value of 94% (95% CI 89-97%)
among participants with CD4 ≥ 100/mm3, and 91%
(95% CI 80-97%) among participants with CD4 < 100/
mm3.
We calculated negative likelihood ratios, which include
sensitivity and specificity in a single formula, to identify
the algorithm with lowest and therefore most favorable
screening profile (Table 4). Overall, presence of any TB-
related symptom had a negative likelihood ratio of 0.57
(95% CI 0.40-0.80), which reduces the post-test probabil-
ity of a patient having active TB from 18% to 11%. The
combination of symptom-based screening and chest
radiography had a negative likelihood ratio of 0.43 (95%
CI 0.29-0.64), which was not significantly better than




Age (years) 34 ± 10
Male gender 359 (53)
Clinical
Prior TB infection 58 (9)
Currently Smoke 165 (24)
Taking a Diuretic Medication 3 (1)
TB-related Symptoms
Any TB-related Symptom 425 (63)
Current cough 242 (36)
Fever 220 (33)
Night sweats 211 (31)
Weight loss 264 (39)
CD4 Cell Count (median/IQR)/mm3 (N = 611) 213 (85, 360)
≥ 100 cells/mm3 437 (74)
< 100 cells/mm3 174 (29)
Radiography
Abnormal chest x-ray 52 (8)
Rapid Urine LAM testing
Positive by Rapid Urine LAM Test 89 (13)
Tuberculosis test results
Sputum smear acid-fast bacilli positive 36 (5)
Culture-confirmed pulmonary TB positive 123 (18)
IQR interquartile range, LAM lipoarabinomannan, SD standard deviation,
TB tuberculosis
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symptom-based screening alone. Incorporating the urine
LAM assay into these screening algorithms lowered the
negative likelihood ratios to 0.45 (95% CI 0.30-0.68) and
0.34 (95% CI 0.22-0.55), respectively. Including urine
LAM in the symptom-based screening algorithm low-
ered the probability of active TB from 11% (using
symptom-based screening alone) to 9%. All negative
likelihood ratios were more favorable for participants
with CD4 < 100/mm3, compared to those with CD4 ≥
100/mm3.
All clinical screening algorithms improved the ability
to exclude pulmonary TB, but those benefits varied by





Positive/Total % (95% CI) Negative/Total % (95% CI) % (95% CI) % (95% CI)
Existing screening algorithms
Cough 66/123 54 (44–63) 376/552 68 (64–72) 27 (22–33) 87 (83–90)
Any TB-related Symptoma 95/123 77 (69–84) 222/552 40 (36–44) 22 (18–27) 89 (84–92)
Any TB-related Symptoma or Abnormal chest x-ray 102/123 83 (75–89) 219/552 40 (36–44) 23 (20–28) 91 (87–95)
Urine LAM alone
Urine LAM Test Positive 38/123 31 (23–39) 508/552 92 (89–94) 46 (35–58) 86 (83–88)
Adding urine LAM to existing screening algorithms
Cough or Urine LAM Positive 84/123 68 (59–76) 353/552 63 (60–68) 30 (24–35) 90 (87–93)
Any TB-related Symptoma or Urine LAM Positive 102/123 83 (75–89) 205/552 37 (33–41) 23 (19–27) 91 (86–94)
Any TB-related Symptoma or Abnormal chest x-ray
or Urine LAM Positive
107/123 87 (80–92) 208/552 38 (34–42) 24 (20–28) 93 (89–96)
CI confidence interval, LAM lipoarabinomannan, PV predictive value, TB tuberculosis
a TB-related symptoms were current cough, fever, night sweats, and weight loss
Table 3 Diagnostic accuracy of TB-related symptoms with and without urine LAM testing for diagnosing culture-confirmed pulmonary
tuberculosis by CD4 count≥ and <100 cell/mm3
Sensitivity Specificity Negative PV
Positive/Total % (95% CI) p-value Negative/Total % (95% CI) p-value % (95% CI) p-value
Cough 0.35 0.005 <0.0001
CD4≥ 100 cells/mm3 25/52 48 (34–62) 270/385 70 (65–75) — 91 (87–94) —
CD4 < 100 cells/mm3 41/71 58 (45–69) 106/167 63 (56–71) — 78 (70–85) —
Cough or Urine LAM Positive 0.24 0.007 0.0002
CD4≥ 100 cells/mm3 32/52 62 (47–75) — 255/385 66 (61–71) — 93 (90–96) —
CD4 < 100 cells/mm3 52/71 73 (61–83) — 98/167 59 (51–66) — 84 (76–90) —
Any TB-related Symptoma 0.05 <0.0001 0.0007
CD4≥ 100 cells/mm3 35/52 67 (53–80) — 168/385 44 (39–49) — 91 (86–95) —
CD4 < 100 cells/mm3 60/71 85 (74–92) — 54/167 32 (25–40) — 83 (72–91) —
Any TB-related Symptoma or Urine LAM Positive 0.09 <0.0001 0.004
CD4≥ 100 cells/mm3 39/52 75 (61–86) — 159/385 41 (36–46) — 92 (87–96) —
CD4 < 100 cells/mm3 63/71 89 (79–95) — 52/167 31 (24–39) — 87 (75–94) —
Any TB-related Symptoma or Abnormal
chest x-ray
0.03 <0.0001 0.007
CD4≥ 100 cells/mm3 38/52 73 (59–84) — 168/385 44 (39–49) — 92 (88–96) —
CD4 < 100 cells/mm3 64/71 90 (81–96) — 51/167 31 (24–38) — 88 (77–95) —
Any TB-related Symptoma or Abnormal chest
x-ray or Urine LAM Positive
0.06 <0.0001 0.03
CD4≥ 100 cells/mm3 41/52 79 (65–89) — 159/385 41 (36–46) — 94 (89–97) —
CD4 < 100 cells/mm3 66/71 93 (84–98) — 49/167 29 (23–37) — 91 (80–97) —
CI confidence interval, LAM lipoarabinomannan, TB tuberculosis
aTB-related symptoms were current cough, fever, night sweats, and weight loss
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the estimated population TB prevalence (Fig. 1). As-
suming a population TB prevalence of 20%, screening
negative for any TB-related symptom decreased the
post-test probability of active TB disease by 37.6%. In
comparison, including urine LAM in the symptom
screening algorithm decreased the post-test probability
by 49.4%, and including both urine LAM and chest
radiography decreased the post-test probability by
60.8%. These differences were more apparent among
populations with a high TB prevalence (20%) as com-
pared to populations with a low (≤ 5%) or moderate TB
prevalence (10%).
Discussion
In this high TB-burden region of South Africa, the
current symptom-based TB screening algorithm per-
formed at initial HIV diagnosis missed nearly one-
quarter of active TB cases, and had many false positive
results. In particular, the WHO’s recommended
symptom-based screening algorithm had a sub-optimal
negative predictive value for detecting active HIV-
associated TB among patients with CD4 < 100 cells/
mm3 in this setting. Additional screening with the
urine LAM assay at HIV diagnosis had marginal benefits
to the existing symptom-based screening algorithm. Urine
LAM testing identified one-quarter (7/28) of TB-infected
adults who did not endorse any TB-related symptom,
which increased the overall diagnostic sensitivity by 6%.
This combined screening algorithm still missed 17% of
active TB cases (83% sensitivity) among all patients,
which does not meet the minimum requirements estab-
lished by the WHO [21, 22]. In addition, this combination
had a high rate of false positive screening results, due
mostly to symptom-based screening. The overall utility of
urine LAM screening improved the negative likelihood ra-
tios, but the changes were modest. Any benefit of urine
LAM appeared to be greatest in populations with a high
estimated TB prevalence and CD4 < 100/mm3.
Our findings are consistent with a meta-analysis of 12
clinical studies that reported a similar diagnostic sensi-
tivity (79%), but higher diagnostic specificity (50%), of
symptom-based screening for culture-confirmed active
TB among HIV-infected adults [7]. The meta-analysis
included observational studies that collected sputum
regardless of symptoms, assessed TB-related symptoms
and HIV status, and used mycobacterial culture as the
gold standard diagnostic test. The addition of chest
radiography in the meta-analysis (defined as positive
symptoms OR chest radiography) increased sensitivity
to 90%, which was higher than our cohort (83%), but
decreased specificity to 39%. Taken together, their cal-
culated negative likelihood ratio was 0.43 by symptom
screening alone and 0.26 when including chest radiog-
raphy, which was lower (better) than our findings.
However, only 3 studies included in the meta-analysis
were conducted in a setting with a TB prevalence
>10%—two were in Southeast Asia [23, 24], and one
South African study had a small sample size with 58
culture-positive TB participants [25]. Our results fur-
ther highlight the urgent need for a better TB screening
algorithm among HIV-infected adults.
The negative predictive value, which changes a pre-
test probability of disease into a post-test probability of
disease, is a critical clinical measure for excluding TB
disease by a screening algorithm [6]. When screening a
population with a high estimated TB prevalence (20%),
the meta-analysis reported a negative predictive value of
the WHO algorithm at 90%, similar to our cohort
Table 4 Screening strategies for diagnosing culture-confirmed pulmonary tuberculosis
Screening without Urine LAM Screening with Urine LAM Difference
LR- (95% CI) LR- (95% CI)
Entire Cohort
Cough 0.68 (0.56–0.83) 0.50 (0.38–0.65) −0.18
Any TB-related Symptoma 0.57 (0.40–0.80) 0.45 (0.30–0.68) −0.12
Any TB-related Symptoma or Abnormal chest x-ray 0.43 (0.29–0.64) 0.34 (0.22–0.55) −0.09
Cohort with CD4≥ 100 cells/mm3
Cough 0.74 (0.57–0.97) 0.58 (0.41–0.83) −0.16
Any TB-related Symptoma 0.75 (0.50–1.12) 0.61 (0.37–0.98) −0.14
Any TB-related Symptoma or Abnormal chest x-ray 0.62 (0.39–0.98) 0.51 (0.30–0.88) −0.11
Cohort with CD4 < 100 cells/mm3
Cough 0.66 (0.50–0.89) 0.46 (0.30–0.68) −0.20
Any TB-related Symptoma 0.48 (0.27–0.86) 0.36 (0.18–0.72) −0.12
Any TB-related Symptoma or Abnormal chest x-ray 0.32 (0.15–0.68) 0.24 (0.10–0.58) −0.08
CI confidence interval, LAM lipoarabinomannan, LR likelihood ratio, TB tuberculosis
aTB-related symptoms were current cough, fever, night sweats, and weight loss
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(89%). While our cohort had a more modest increase
with the addition of chest radiography (89% to 91%),
the most significant impact was achieved when adding
both urine LAM and chest radiography (93%). In this
algorithm, 7% of those who screening negative will still
have active TB disease, which highlights the continued
need for an improved screening algorithm.
The consequences of inaccurate TB screening among
HIV-infected adults are severe, and include missed diag-
nosis and inappropriate treatment of active TB, unneces-
sary delays for antiretroviral therapy and isoniazid
preventive therapy (IPT) initiation while awaiting sputum-
based diagnostic testing, inadequate provision of IPT,
overprescribing of empiric TB therapy, and high loss to
follow-up rates with increased program costs [8, 26]. For
these reasons, the WHO has prioritized a rapid screening
test that can be used by first-contact health care providers
to screen for active TB, which will “triage” patients to ei-
ther receive immediate IPT or diagnostic sputum-based
testing with the Xpert MTB/RIF assay [21, 22]. Since the
urine LAM test meets several of the WHO requirements
(specificity > 70%, point-of-care test with minimal steps,
time to result < 30 minutes) [21, 22], but falls short of
having > 90% diagnostic sensitivity [13–15], groups are
working to develop a more sensitive urinary LAM
assay. In an Ethiopian cohort, increasing the LAM
assay detection 50-fold by using high-avidity monoclo-
nal antibodies improved the diagnostic sensitivity of
urine LAM testing to 93% [27].
Our study had several additional strengths and limita-
tions. Primary strengths were evaluating the urine LAM
assay when used by trained nurses in ambulatory set-
tings, which is similar to a real-world application, asses-
sing both liquid and solid mycobacterial culture as the
gold standard, enrolling people prior to HIV diagnosis
and ART initiation, and assessing urine LAM among
people with a range of CD4 counts. Limitations included
obtaining a single sputum sample for mycobacterial cul-
ture and not performing a comprehensive evaluation for
extrapulmonary TB, both of which could have misclassi-
fied people as not having TB due to an imperfect refer-
ence standard. We excluded the patients who did not
provide a urine or sputum sample. Although this study
was among the largest TB screening studies in HIV-
infected adults [7], a limited sample size prevented the
detection of statistically significant differences in im-
proved diagnostic sensitivity and negative predictive
values, or reduced negative likelihood ratios, for new
screening algorithms. The WHO guidelines recommend
that HIV-infected adults be screened for TB at every
visit to a health facility or contact with a health worker,
which we did not evaluate in our study.
Conclusions
In conclusion, our results demonstrate a marginal benefit
from the inclusion of rapid urine LAM screening to clin-
ical symptom screening among ART-naïve HIV-infected
adults in resource-constrained TB-endemic regions. Fu-
ture studies should examine the role of point-of-care test-
ing to expedite initiation of anti-TB therapy and include a
cost-effectiveness analysis for clinic-based LAM screening.
The current urine LAM assay is imperfect and does not
solve the public health challenge of screening or diagnos-
ing TB. However, since the principles behind the urine
LAM assay are sound, an improved, next-generation urin-
ary LAM assay could meet the criteria for a rapid, clinic-
based TB screening test among HIV-infected adults in
TB-endemic settings.
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